Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AUPH Aurinia Pharmaceuticals	$8.14 -0.5%	$7.99	$5.20 ▼ $10.67	$1.10B	1.15	1.33 million shs	977,879 shs
NAGE Niagen Bioscience	$14.14 +3.7%	$9.25	$2.31 ▼ $14.49	$1.11B	2.08	857,190 shs	785,147 shs
TNXP Tonix Pharmaceuticals	$36.97 +15.6%	$25.07	$6.76 ▼ $137.25	$270.81M	2.09	925,152 shs	731,037 shs
WVE Wave Life Sciences	$6.85 -1.4%	$6.52	$4.25 ▼ $16.74	$1.06B	-1.04	1.32 million shs	560,838 shs

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AUPH Aurinia Pharmaceuticals	0.00%	-0.12%	-0.12%	-2.62%	+44.78%
NAGE Niagen Bioscience	0.00%	+5.25%	+24.47%	+71.66%	+357.38%
TNXP Tonix Pharmaceuticals	0.00%	-21.33%	+14.21%	+96.44%	-72.19%
WVE Wave Life Sciences	0.00%	-3.74%	+9.79%	-31.66%	+11.56%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AUPH Aurinia Pharmaceuticals	3.286 of 5 stars	3.5	2.0	0.0	4.1	0.8	1.9
NAGE Niagen Bioscience	1.4546 of 5 stars	3.5	0.0	0.0	2.6	0.0	0.0
TNXP Tonix Pharmaceuticals	3.3775 of 5 stars	3.5	2.0	0.0	3.2	3.3	1.3
WVE Wave Life Sciences	4.2712 of 5 stars	3.5	1.0	4.8	2.1	4.2	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AUPH Aurinia Pharmaceuticals	3.00	Buy	$11.50	41.28% Upside
NAGE Niagen Bioscience	3.00	Buy	$19.50	37.91% Upside
TNXP Tonix Pharmaceuticals	3.00	Buy	$585.00	1,482.36% Upside
WVE Wave Life Sciences	2.92	Moderate Buy	$20.50	199.27% Upside

Current Analyst Ratings Breakdown

Latest TNXP, AUPH, WVE, and NAGE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/11/2025	WVE Wave Life Sciences	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$14.00
6/10/2025	NAGE Niagen Bioscience	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$13.00 ➝ $16.00
6/6/2025	NAGE Niagen Bioscience	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $23.00
6/3/2025	TNXP Tonix Pharmaceuticals	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/27/2025	NAGE Niagen Bioscience	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$13.00
4/29/2025	WVE Wave Life Sciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$10.00
4/8/2025	WVE Wave Life Sciences	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$18.00
3/26/2025	WVE Wave Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00 ➝ $22.00
3/20/2025	TNXP Tonix Pharmaceuticals	Noble Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$70.00 ➝ $70.00

(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AUPH Aurinia Pharmaceuticals	$247.30M	4.45	N/A	N/A	$2.63 per share	3.10
NAGE Niagen Bioscience	$107.93M	10.32	N/A	N/A	N/A	∞
TNXP Tonix Pharmaceuticals	$10.04M	26.97	N/A	N/A	$5,751.80 per share	0.01
WVE Wave Life Sciences	$104.94M	10.06	N/A	N/A	$0.40 per share	17.13

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AUPH Aurinia Pharmaceuticals	-$78.02M	$0.28	N/A	14.54	N/A	-10.23%	-4.41%	-3.07%	7/30/2025 (Estimated)
NAGE Niagen Bioscience	N/A	$0.17	83.18	∞	N/A	N/A	N/A	N/A	N/A
TNXP Tonix Pharmaceuticals	-$116.66M	-$1,963.61	N/A	N/A	N/A	-1,197.86%	-163.95%	-118.88%	8/15/2025 (Estimated)
WVE Wave Life Sciences	-$57.51M	-$0.84	N/A	N/A	N/A	-66.50%	-280.57%	-52.90%	8/6/2025 (Estimated)

Latest TNXP, AUPH, WVE, and NAGE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	AUPH Aurinia Pharmaceuticals	$0.08	$0.16	+$0.08	$0.16	$61.06 million	$62.47 million
5/12/2025	Q1 2025	TNXP Tonix Pharmaceuticals	-$3.23	-$2.84	+$0.39	-$2.84	$2.55 million	$2.43 million
5/8/2025	Q1 2025	WVE Wave Life Sciences	-$0.27	-$0.29	-$0.02	-$0.29	$11.65 million	$9.18 million
3/18/2025	Q4 2024	TNXP Tonix Pharmaceuticals	-$6.23	-$9.77	-$3.54	-$9.77	$3.20 million	$2.58 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AUPH Aurinia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NAGE Niagen Bioscience	N/A	N/A	N/A	N/A	N/A
TNXP Tonix Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
WVE Wave Life Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AUPH Aurinia Pharmaceuticals	0.17	5.60	5.11
NAGE Niagen Bioscience	N/A	N/A	N/A
TNXP Tonix Pharmaceuticals	0.07	3.33	2.81
WVE Wave Life Sciences	N/A	1.90	1.90

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AUPH Aurinia Pharmaceuticals	36.83%
NAGE Niagen Bioscience	15.41%
TNXP Tonix Pharmaceuticals	82.26%
WVE Wave Life Sciences	89.73%

Insider Ownership

Company	Insider Ownership
AUPH Aurinia Pharmaceuticals	12.20%
NAGE Niagen Bioscience	9.39%
TNXP Tonix Pharmaceuticals	0.03%
WVE Wave Life Sciences	29.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AUPH Aurinia Pharmaceuticals	300	135.10 million	137.02 million	Optionable
NAGE Niagen Bioscience	120	78.77 million	N/A	N/A
TNXP Tonix Pharmaceuticals	50	7.33 million	1.87 million	Not Optionable
WVE Wave Life Sciences	240	154.13 million	108.14 million	Optionable

TNXP, AUPH, WVE, and NAGE Headlines

Recent News About These Companies

Wave Life Sciences Ltd. (NASDAQ:WVE) Director Sells $208,500.00 in Stock

June 14 at 7:51 AM | insidertrades.com

Wave Life Sciences Ltd. (NASDAQ:WVE) Receives $21.17 Average Target Price from Analysts

June 14 at 2:20 AM | americanbankingnews.com

Wave Life Sciences Ltd. (NASDAQ:WVE) Director Gregory L. Verdine Sells 30,000 Shares

June 13 at 8:41 PM | marketbeat.com

Wave Life Sciences (NASDAQ:WVE) Coverage Initiated by Analysts at Raymond James

June 12, 2025 | americanbankingnews.com

Cantor Fitzgerald Comments on WVE FY2026 Earnings

June 12, 2025 | americanbankingnews.com

Wave Life Sciences (NASDAQ:WVE) Now Covered by Raymond James

June 11, 2025 | marketbeat.com

Wave Life Sciences Ltd. (NASDAQ:WVE) Receives Average Recommendation of "Buy" from Analysts

June 11, 2025 | marketbeat.com

Brokers Offer Predictions for WVE FY2026 Earnings

June 10, 2025 | marketbeat.com

Wave Life Sciences (NASDAQ:WVE) Shares Down 4.6% - Here's Why

June 9, 2025 | marketbeat.com

Two Sigma Advisers LP Buys Shares of 68,100 Wave Life Sciences Ltd. (NASDAQ:WVE)

June 3, 2025 | marketbeat.com

Universal Beteiligungs und Servicegesellschaft mbH Acquires Shares of 362,291 Wave Life Sciences Ltd. (NASDAQ:WVE)

June 2, 2025 | marketbeat.com

Nuveen Asset Management LLC Has $6.85 Million Stock Position in Wave Life Sciences Ltd. (NASDAQ:WVE)

May 31, 2025 | marketbeat.com

Wave Life Sciences to Present at 2025 Jefferies Global Healthcare Conference

May 29, 2025 | globenewswire.com

Wave Life Sciences Ltd. (NASDAQ:WVE) Shares Acquired by Two Sigma Investments LP

May 29, 2025 | marketbeat.com

Bank of America Corp DE Acquires 160,820 Shares of Wave Life Sciences Ltd. (NASDAQ:WVE)

May 29, 2025 | marketbeat.com

Wave Life Sciences Announces Appointment of Dr. Christopher Wright as Chief Medical Officer

May 28, 2025 | globenewswire.com

Polar Asset Management Partners Inc. Has $6.89 Million Position in Wave Life Sciences Ltd. (NASDAQ:WVE)

May 28, 2025 | marketbeat.com

845,830 Shares in Wave Life Sciences Ltd. (NASDAQ:WVE) Purchased by Voloridge Investment Management LLC

May 27, 2025 | marketbeat.com

Wave Life Sciences Ltd. (NASDAQ:WVE) Holdings Lifted by Millennium Management LLC

May 25, 2025 | marketbeat.com

BNP Paribas Financial Markets Increases Stake in Wave Life Sciences Ltd. (NASDAQ:WVE)

May 20, 2025 | marketbeat.com

Wave Life Sciences Ltd. (NASDAQ:WVE) Holdings Increased by Northern Trust Corp

May 19, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNXP, AUPH, WVE, and NAGE Company Descriptions

Aurinia Pharmaceuticals NASDAQ:AUPH

$8.14 -0.04 (-0.49%)

Closing price 04:00 PM Eastern

Extended Trading

$8.24 +0.10 (+1.18%)

As of 04:04 PM Eastern

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

Niagen Bioscience NASDAQ:NAGE

$14.14 +0.51 (+3.74%)

As of 04:00 PM Eastern

Niagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.

Tonix Pharmaceuticals NASDAQ:TNXP

$36.97 +4.99 (+15.60%)

Closing price 04:00 PM Eastern

Extended Trading

$36.50 -0.47 (-1.27%)

As of 04:39 PM Eastern

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey.

Wave Life Sciences NASDAQ:WVE

$6.85 -0.10 (-1.44%)

Closing price 04:00 PM Eastern

Extended Trading

$6.80 -0.05 (-0.80%)

As of 04:09 PM Eastern

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time